SG11201805838UA - Macrocyclic mcl1 inhibitors for treating cancer - Google Patents
Macrocyclic mcl1 inhibitors for treating cancerInfo
- Publication number
- SG11201805838UA SG11201805838UA SG11201805838UA SG11201805838UA SG11201805838UA SG 11201805838U A SG11201805838U A SG 11201805838UA SG 11201805838U A SG11201805838U A SG 11201805838UA SG 11201805838U A SG11201805838U A SG 11201805838UA SG 11201805838U A SG11201805838U A SG 11201805838UA
- Authority
- SG
- Singapore
- Prior art keywords
- astrazeneca
- waltham
- drive
- gatehouse
- international
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 MI 11111 0 11101 HOE 010 1111 1 0 I OEM OH 1101 OHO 11110 MAMIE Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\" WO 2017/182625 Al 26 October 2017 (26.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07D 515/22 (2006.01) A61P 35/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61K 31/395 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, PCT/EP2017/059511 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 21 April 2017 (21.04.2017) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/326,156 22 April 2016 (22.04.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Sodertalje (SE). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (72) Inventors: HIRD, Alexander; AstraZeneca 35 Gate- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, house Drive, MA, Waltham 02451 (US). BELMONTE, KM, ML, MR, NE, SN, TD, TG). _ Matthew, Alan; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). YANG, Wenzhan; AstraZeneca Declarations under Rule 4.17: 35 Gatehouse Drive, MA, Waltham 02451 (US). SE- — as to applicant's entitlement to apply for and be granted a CRIST, John, Paul; AstraZeneca 35 Gatehouse Drive, patent (Rule 4.17(ii)) = MA, Waltham 02451 (US). ROBBINS, Daniel, William; Published: AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 — with international search report (Art. 21(3)) (US). KAZMIRSKI, Steven, Lee; AstraZeneca 35 Gate- — with sequence listing part of description (Rule 5.2(a)) house Drive, MA, Waltham 02451 (US). WU, Dedong; = — AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 = (US). PENG, Bo; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). JOHANNES, Jeffrey; AstraZeneca = 35 Gatehouse Drive, MA, Waltham 02451 (US). LAMB, Michelle, Laurae; AstraZeneca 35 Gatehouse Drive, MA, Waltham 02451 (US). YE, Oing; AstraZeneca 35 Gate- = = house Drive, MA, Waltham 02451 (US). ZHENG, Xi- _ aolan; AstraZeneca 35 Gatehouse Drive, MA, Waltham = 02451 (US). = (74) Agent: NESS, Mark; Milstein Building Granta Park, Cam- bridge Cambridgeshire CB21 6GH (GB). = (81) Designated States (unless otherwise indicated, for every = _ kind of national protection available): AE, AG, AL, AM, = Title: MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCER = (54) (57) : Disclosed is a compound which is 17-chloro-5,13,14,22-tetram- ethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo [27.7.1.14,7.011,15. _— 1-1 016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tride- fl caene-23-carboxylic acid (Formula I) and enantiomers and phar- in maceutically acceptable salts thereof. Also disclosed are phar- ei maceutical compositions of 17-chloro-5,13,14,22-tetramethy1-28-oxa-2,9- VZ+ ei ( 1 ) dithia- 5,6,12,13,22 -pentaazaheptacyclo [27.7.1.14,7.011,15.016,21.020,24.030,35]octatri- cc c OH aconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35 -tridecaene-23 -carboxylic acid, and 1-1 enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer IN S N with such compounds and compositions. 1-1 N—N ei 0 O
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805838UA true SG11201805838UA (en) | 2018-11-29 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805838UA SG11201805838UA (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (en) |
| EP (1) | EP3445767B1 (en) |
| JP (1) | JP6894449B2 (en) |
| KR (1) | KR102388208B1 (en) |
| CN (1) | CN109071566B (en) |
| AR (1) | AR108301A1 (en) |
| AU (1) | AU2017252222B2 (en) |
| BR (1) | BR112018070677B1 (en) |
| CA (1) | CA3020378A1 (en) |
| CL (1) | CL2018002410A1 (en) |
| CO (1) | CO2018008759A2 (en) |
| CR (1) | CR20180499A (en) |
| CY (1) | CY1123186T1 (en) |
| DK (1) | DK3445767T3 (en) |
| DO (1) | DOP2018000222A (en) |
| EA (1) | EA036551B1 (en) |
| ES (1) | ES2791319T3 (en) |
| HR (1) | HRP20200673T1 (en) |
| HU (1) | HUE049591T2 (en) |
| IL (1) | IL262237B (en) |
| LT (1) | LT3445767T (en) |
| MA (1) | MA44721B1 (en) |
| ME (1) | ME03729B (en) |
| MX (1) | MX2018012711A (en) |
| NI (1) | NI201800093A (en) |
| PE (1) | PE20181803A1 (en) |
| PH (1) | PH12018502227A1 (en) |
| PL (1) | PL3445767T3 (en) |
| PT (1) | PT3445767T (en) |
| RS (1) | RS60257B1 (en) |
| SG (1) | SG11201805838UA (en) |
| SI (1) | SI3445767T1 (en) |
| SV (1) | SV2018005742A (en) |
| TN (1) | TN2018000319A1 (en) |
| TW (1) | TWI742074B (en) |
| WO (1) | WO2017182625A1 (en) |
| ZA (1) | ZA201807766B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| MX2018009408A (en) | 2016-02-04 | 2018-11-09 | Univ Johns Hopkins | Rapaglutins, novel inhibitors of glut and use thereof. |
| CA3013650A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| JP6894449B2 (en) | 2016-04-22 | 2021-06-30 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Macrocyclic MCL1 inhibitor for treating cancer |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (en) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | Methods of synthesizing an mcl-1 inhibitor |
| TW201904976A (en) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Mcl-1 inhibitors and methods of use thereof |
| UA126586C2 (en) | 2017-08-15 | 2022-11-02 | Еббві Інк. | Macrocyclic mcl-1 inhibitors and methods of use |
| BR112020003163A2 (en) * | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | macrocyclic mcl-1 inhibitors and methods of use |
| UY37971A (en) | 2017-11-17 | 2019-06-28 | Bayer Ag | SUBSTITUTED MACROCYCLIC INDOL DERITATES |
| US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| WO2019096911A1 (en) | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| AR113887A1 (en) | 2017-11-17 | 2020-06-24 | Bayer Ag | MACROCYCLIC INDEOL DERIVATIVES REPLACED WITH CHLORINE |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| TW202014184A (en) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | Combinations for treating cancer |
| WO2020063792A1 (en) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TWI810397B (en) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | Methods of treating cancer |
| CN111205309B (en) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Indole macrocyclic derivatives, preparation method and medical application thereof |
| TWI749404B (en) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | Macrocyclic indole as MCL-1 inhibitor |
| TWI760685B (en) * | 2019-01-23 | 2022-04-11 | 大陸商蘇州亞盛藥業有限公司 | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| EP3924358A4 (en) * | 2019-03-08 | 2023-07-05 | Zeno Management, Inc. | Macrocyclic compounds |
| CN113574058B (en) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | Indole macrocyclic derivative, preparation method and medical application thereof |
| PE20220218A1 (en) | 2019-05-20 | 2022-02-02 | Novartis Ag | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| WO2020254471A1 (en) | 2019-06-21 | 2020-12-24 | Janssen Pharmaceutica Nv | Macrocyclic inhibitors of mcl-1 |
| CN114096546A (en) | 2019-07-09 | 2022-02-25 | 詹森药业有限公司 | Macrocyclic spirocyclic derivatives useful as MCL-1 inhibitors |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| AU2020388974A1 (en) | 2019-11-21 | 2022-07-07 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as MCL-1 inhibitors |
| CA3157731A1 (en) | 2019-11-21 | 2021-05-27 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as mcl-1 inhibitors |
| WO2021126316A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3168355A1 (en) | 2020-02-21 | 2021-08-26 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| CN115335384A (en) * | 2020-03-30 | 2022-11-11 | 江苏恒瑞医药股份有限公司 | Crystal form of indole macrocyclic derivative and preparation method thereof |
| US20230265105A1 (en) | 2020-05-29 | 2023-08-24 | Janssen Pharmaceutica Nv | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| CA3181816A1 (en) | 2020-06-19 | 2021-12-23 | Aldo Peschiulli | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2021291056A1 (en) | 2020-06-19 | 2023-02-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| BR112023000212A2 (en) | 2020-07-08 | 2023-01-31 | Janssen Pharmaceutica Nv | MACROCYCLIC ETHER CONTAINING INDOL DERIVATIVES AS MCL-1 INHIBITORS |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| JP2023553808A (en) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | MCL-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| CN116710458A (en) | 2020-12-17 | 2023-09-05 | 詹森药业有限公司 | Branched macrocyclic 4- (pyrazol-5-yl) -indole derivatives as MCL-1 inhibitors |
| CA3206202A1 (en) | 2021-02-12 | 2022-08-18 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| CA3222752A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| CN115490708A (en) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | Sulfonamide macrocyclic derivatives, and preparation method and application thereof |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
| KR101511074B1 (en) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-Substituted indole Mcl-1 inhibitors |
| PL2379580T3 (en) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Novel antibacterial agents for the treatment of gram positive infections |
| WO2011079007A1 (en) * | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| PT2710018T (en) * | 2011-05-19 | 2022-03-01 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | New compounds |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| WO2015031608A1 (en) | 2013-08-28 | 2015-03-05 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| PT3105236T (en) * | 2014-02-12 | 2017-12-22 | Viiv Healthcare Uk (No 5) Ltd | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| CA2943815C (en) | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| EP3129387B1 (en) * | 2014-04-11 | 2019-06-26 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| JP6894449B2 (en) | 2016-04-22 | 2021-06-30 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Macrocyclic MCL1 inhibitor for treating cancer |
-
2017
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/en active Active
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/en active IP Right Grant
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 SI SI201730246T patent/SI3445767T1/en unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/en active IP Right Grant
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/en unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/en unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/en unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/en unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/en unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/en unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/en unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/en unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 ES ES17720720T patent/ES2791319T3/en active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/en unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/en active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/en unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/en not_active IP Right Cessation
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/en active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/en unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/en active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/en unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/en unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/en unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/en unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/en unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/en unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/en unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201808842VA (en) | Heteroaryl substituted pyridines and methods of use | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201907334QA (en) | Therapeutic dendrimers | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201407326XA (en) | Compositions and methods for treatment of mucositis | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201407317SA (en) | Compositions and methods for suppression of carbonic anhydrase activity | |
| SG11201901460UA (en) | Method for producing the crystalline form of modification a of calcobutrol | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201903091VA (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |